

Health Technology Clinical Committee

Date: May 19, 2023
Time: 8:00 a.m. – 3:00 p.m.
Location: Webinar
Adopted: June 23, 2023

Meeting materials and transcript are available on the [HTA website](#).

HTCC Minutes

Members present: Clinton Daniels, DC, MS; Janna Friedly, MD, MPH; Christoph Lee, MD, MS; Laurie Mischley, ND, MPH, PhD; Sheila Rege, MD; Jonathan Sham, MD; Tony Yen, MD

Clinical expert: Simon Lo, MD

HTCC Formal Action

- Welcome and Chair remarks:** Dr. Rege, chair, called the meeting to order; members present constituted a quorum.
- HTA program updates:** Josh Morse, program director, presented HTCC meeting protocols and guidelines, and an overview of the HTA program.
- Previous meeting business:**

March 17, 2023 meeting minutes: Draft minutes reviewed. Motion made and seconded to approve the minutes as written.

Action: Six committee members approved the March 17, 2023 meeting minutes.

Vote on transcranial magnetic stimulation findings and decision:

Action: Five committee members voted on draft TMS findings and decision, which was below quorum and will be voted on again at a future meeting.

- Stereotactic body radiation therapy**

Washington State agency utilization and outcomes: Sophie Miller, MD, MPH, Medical Officer for Medicaid, Health Care Authority, presented the state agency perspective on stereotactic body radiation therapy. Find the full presentation published with the [May 19 meeting materials](#).

Scheduled and open public comments: Chair called for public comments. Comments were provided by:

- Robert Meier, MD – Radiation Oncology Medical Director; Providence Swedish Radiosurgery Center; Seattle, WA
- Christopher Loisel, MD – Executive Medical Director; Providence Swedish Radiosurgery Center; Seattle, WA

Final

- Edward Kim, MD – Associate Professor; University of Washington; Seattle, WA
- Smith ‘Jim’ Apisarnthanarax, MD – Professor; University of Washington; Seattle, WA

Vendor report/HTCC questions and answers: Beth Shaw, MSc, Center for Evidence Based Policy, presented the evidence review for stereotactic body radiation therapy. The full presentation is published with the [May 19 meeting materials](#).

HTCC discussion and action:

Discussion

The committee reviewed and discussed the available studies for use of SBRT for prostate, lung, pancreatic adenocarcinoma, liver, oligometastatic, kidney, adrenal, head and neck, and bone cancers. Details of study design, inclusion criteria, outcomes, cost, cost-effectiveness, and other factors affecting study quality were discussed. During discussion, the committee considered the evidence, public comment and expert input, and gave greatest weight to the evidence it determined, based on objective factors, to be the most valid and reliable. Conditions for coverage were discussed and a draft was started, but not completed by the time the meeting was adjourned.

Action

The committee chair directed HTA staff to establish a follow up meeting to finalize discussion on SBRT to produce a draft findings and decision.

5. Meeting adjourned